therefore, while suppression is often noticed early, it usually intensifies as the dosage is gradually titrated up over several months
In 2025, the company delivered a solid +8.56% YoY revenue growth, driven by its immunology portfolio: Skyrizi ($17.56B) continues to surge with strong uptake across psoriasis and IBD, Rinvoq ($8.3B) is expanding rapidly across multiple inflammatory conditions, while Humira ($4.54B) continues to decline following loss of exclusivity marking a clear shift toward newer growth assets
Missing three or more doses effectively resets your body tolerance
2023;63(4S):s25-s30
What drugmakers are arguing about now is what kind of weight comes off, whether patients are losing fat or muscle, and what other benefits could be gained from these drugs
As well as favorable reimbursement policies with government support for diabetes and obesity treatments, are a boost in access to cost-effective medications